Crossref is a non-profit organization that logs and updates citations for scientific publications. Each month, Crossref identifies a list of the most popular Oncotarget papers based on the number of times a DOI is successfully resolved.
Below are Crossref’s Top 10 Oncotarget DOIs published in 2023.
10: Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)
DOI: https://doi.org/10.18632/oncotarget.28355
Authors: Md Maksudul Alam, Janmaris Marin Fermin, Mark Knackstedt, Mackenzie J. Noonan, Taylor Powell, Landon Goodreau, Emily K. Daniel, Xiaohua Rong, Tara Moore-Medlin, Alok R. Khandelwal, and Cherie-Ann O. Nathan
9: Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer
DOI: https://doi.org/10.18632/oncotarget.28353
Authors: Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Hikota Hayashi, Yohei Sasaki, Koki Kawakami, Ryoji Hyakudomi, Tetsu Yamamoto, and Yoshitsugu Tajima
8: Crosstalk between triple negative breast cancer and microenvironment
DOI: https://doi.org/10.18632/oncotarget.28397
Authors: Karly Smrekar, Artem Belyakov and Kideok Jin
7: Systemic AL amyloidosis: current approach and future direction
DOI: https://doi.org/10.18632/oncotarget.28415
Authors: Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, and Chakra P. Chaulagain
6: Deciphering the mechanisms of action of progesterone in breast cancer
DOI: https://doi.org/10.18632/oncotarget.28455
Authors: Gaurav Chakravorty, Suhail Ahmad, Mukul S. Godbole, Sudeep Gupta, Rajendra A. Badwe, and Amit Dutt
5: Targeting cellular respiration as a therapeutic strategy in glioblastoma
DOI: https://doi.org/10.18632/oncotarget.28424
Authors: Enyuan Shang, Trang Thi Thu Nguyen, Mike-Andrew Westhoff, Georg Karpel-Massler, and Markus D. Siegelin
4: Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
DOI: https://doi.org/10.18632/oncotarget.28382
Author: Mikhail V. Blagosklonny, M.D., Ph.D.
3: The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy
DOI: https://doi.org/10.18632/oncotarget.28354
Authors: Anqi Shao and David M. Owens
2: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss
DOI: https://doi.org/10.18632/oncotarget.28376
Authors: Maroun Bou Zerdan, Prashanth Ashok Kumar, Elio Haroun, Nimisha Srivastava, Jeffrey Ross, and Abirami Sivapiragasam
1: Using cancer proteomics data to identify gene candidates for therapeutic targeting
DOI: https://doi.org/10.18632/oncotarget.28420
Authors: Diana Monsivais, Sydney E. Parks, Darshan S. Chandrashekar, Sooryanarayana Varambally, and Chad J. Creighton
Oncotarget is an open-access, peer-reviewed journal that has published primarily oncology-focused research papers since 2010. These papers are available to readers (at no cost and free of subscription barriers) in a continuous publishing format at Oncotarget.com. Oncotarget is indexed/archived on MEDLINE / PMC / PubMed.
For media inquiries, please contact media@impactjournals.com.
